- Home
- PGEN
PGEN
Precigen Inc.
as 10-24-2025 3:54pm EST
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | GERMANTOWN |
| Market Cap: | 493.0M | IPO Year: | N/A |
| Target Price: | $7.50 | AVG Volume (30 days): | 5.2M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.65 - $5.22 | Next Earning Date: | 11-13-2025 |
| Revenue: | $4,340,000 | Revenue Growth: | -1.12% |
| Revenue Growth (this year): | 249.1% | Revenue Growth (next year): | 710.03% |
Stock Insider Trading Activity of Precigen Inc. (PGEN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KIRK RANDAL J | PGEN | Director, 10% Owner | Sep 30 '25 | Sell | $3.41 | 1,809,667 | $6,170,964.47 | 14,597,161 | |
| KINDLER JEFFREY B | PGEN | Director | Sep 30 '25 | Sell | $3.38 | 106,837 | $361,109.06 | 346,070 | |
| Tennant Phil | PGEN | Chief Commercial Officer | Sep 29 '25 | Buy | $3.58 | 6,000 | $21,480.00 | 65,031 | |
| KINDLER JEFFREY B | PGEN | Director | Sep 29 '25 | Sell | $3.60 | 67,523 | $243,082.80 | 346,070 | |
| Thomasian Harry Jr. | PGEN | Chief Financial Officer | Sep 26 '25 | Buy | $3.42 | 2,932 | $10,027.44 | 468,626 | |
| Shah Rutul R | PGEN | Chief Operating Officer | Sep 26 '25 | Buy | $3.40 | 2,000 | $6,800.00 | 405,959 | |
| Thomasian Harry Jr. | PGEN | Chief Financial Officer | Sep 25 '25 | Buy | $3.62 | 8,284 | $29,988.08 | 468,626 | |
| AGEE NANCY H | PGEN | Director | Sep 4 '25 | Buy | $4.60 | 15,000 | $69,000.00 | 217,841 | |
| AGEE NANCY H | PGEN | Director | Aug 28 '25 | Buy | $4.65 | 10,645 | $49,490.73 | 217,841 | |
| AGEE NANCY H | PGEN | Director | Aug 19 '25 | Buy | $3.20 | 15,360 | $49,152.00 | 217,841 |
Latest Precigen Inc. News
PGEN Breaking Stock News: Dive into PGEN Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
Sector Update: Health Care Stocks Higher Premarket Monday
MT Newswires
12 days ago
Precigen Says Drug for Rare Respiratory Disease Shows Durable Outcomes
PR Newswire
12 days ago
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
Pharma Voice
a month ago
4 years from clinic to approval — Precigen’s ‘unprecedented’ FDA nod and what comes next
PR Newswire
a month ago
EVERSANA Named by Precigen for U.S. Commercialization of PAPZIMEOS
Insider Monkey
a month ago
Precigen’s (PGEN) Papzimeos Push Sparks Multibagger Ascent, Boosted by Analyst Optimism
Simply Wall St.
4 months ago
High Growth Tech Stocks To Watch In The US June 2025
Simply Wall St.
4 months ago
Precigen, Inc.'s (NASDAQ:PGEN) market cap touched US$455m last week, benefiting both private equity firms who own 33% as well as institutions
Compare PGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PGEN Precigen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.